JJBC
MDGL icon

James J. Burns & Company’s Madrigal Pharmaceuticals MDGL Stock Holding History

James J. Burns & Company’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Hold
532
– – 0.03% 136
2026
Q1 		$278K Hold
532
– – 0.04% 130
2025
Q4 		$310K Buy
+532
New +$272K 0.04% 128

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

James J. Burns & Company's MDGL Position: Q2 2026 in Review

James J. Burns & Company held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 532 shares worth $286K. The position accounts for 0.03% of the portfolio, ranked #136.

James J. Burns & Company first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $310K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • James J. Burns & Company held 532 shares of Madrigal Pharmaceuticals worth $286K as of Q2 2026.
  • James J. Burns & Company left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.03% of James J. Burns & Company's portfolio in Q2 2026, its #136 holding.
  • James J. Burns & Company first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • James J. Burns & Company's Madrigal Pharmaceuticals position peaked at $310K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on James J. Burns & Company's 13F filing for Q2 2026, filed 6 Aug 2026.